Today's Brief

Updated daily.

Get the free BIOTECH brief in 5 minutes.

A free daily and weekly email that tells you what changed, what is noise, and where to verify it at the source.

Start with the short list before you open another feed.
See what is continuing versus what is only today's spike.
Open the original sources in one click when you want to verify.

Free daily + weekly email

Free by email: Today’s Brief (daily) + This Week’s Brief (weekly). Upgrade later for archive, alerts, search, exports, API, and workflow.

Get tomorrow's brief by email

One field, compact consent, daily + weekly by default.

How it works Open featured signal

What you would receive

Featured now

Jeito Capital closes record $1.2 billion fund for European biopharma

Jeito Capital has raised $1.2 billion, marking the largest ever fund by an independent European biopharma-focused venture firm. The capital will support 15 to 20 clini...

Why now: The fund closing reflects growing momentum and capital flow into European biopharma amid a competitive global biotech investment landscape.

biopharmadive.com
BioPharma Dive
pharmaphorum
Jeito closes 'record' $1.2bn Europe-focused biopharma fund
Fierce Biotech
Jeito Capital has hailed the $1.2 billion it has secured as the “largest raise ever achieved” by an independent biopharma-focused European fund.

All source links included.

Open today's sample Browse signals

Read today's brief Browse signals

Today’s strongest item first

The homepage leads with an editorially featured signal alongside the open brief, while current signals stay open across the site.

Proof, not boilerplate

3 real source links are already visible in today’s public example.

Free brief before upgrade

Get the daily + weekly brief by email first. Upgrade only if you need archive, alerts, search, exports, API, and deeper workflow tools.

What lands in your free brief

Start with the brief, then drill down only on the items that matter.

Briefing item

Roche and Gilead expand oncology pipelines with protein degrader partnerships

Roche and Gilead are advancing their oncology drug development by investing in protein degrader therapies. Roche committed $20 million upfront plus over $1 billion in milestones to partner with C4 Therapeutics on two antibody-targeted protein degrader programs.

Why now: Roche and Gilead recently made major investments in degrader technologies.

CurrentSource diversity aware

Sources: 2

See details ->

Briefing item

New computational frameworks advance spatial transcriptomics analysis in cancer research

Recent studies introduce innovative computational methods to enhance spatial transcriptomics analysis, enabling deeper insights into cell-cell communication, regulatory programs, and tumor microenvironment heterogeneity.

Why now: Rapid advances in spatial transcriptomics technologies generate complex data requiring novel analytical frameworks.

CurrentSource diversity aware

Sources: 5

See details ->

Briefing item

New molecular insights into proteins shaping synapse formation and neural circuit development

Recent studies reveal critical roles of specific proteins in neuronal development, synaptic connectivity, and brain circuit wiring.

Why now: Recent studies provide new molecular insights into neuronal development and synaptic connectivity.

CurrentSource diversity aware

Sources: 3

See details ->

How it works

Built to save you time while keeping every key point easy to verify.

Read widely

News, social, dev channels, and primary sources.

Remove duplicates

Filter rewrites, SEO clones, and repeated takes.

Group what belongs together

So you see one story, not 20 scattered posts.

Deliver the briefing

A daily scan + drill-down with source links.

See Methodology

Start free, upgrade only if you need more

Start with the free brief if you want the signal first, not an hour of scrolling. It gives you the short list, the context, and the source links in one pass.

Upgrade later only if you need memory, alerts, archive, exports, API, and recurring workflow for ongoing research work.

Why people start with the free brief

Daily brief

The 5-minute version of what genuinely changed since yesterday.

Momentum over time

See what is building, peaking, or fading across days and weeks.

Source links included

Jump to the originals when you need to verify a claim fast.

Free daily + weekly emailUpgrade only when you need full drill-down

Get the free brief

See pricing This Week’s Brief

Product tour

A short walkthrough of the BIOTECH dashboards.